Episode 115
On this week’s Biotech Hangout, hosts Josh Schimmer, Brad Loncar, Sam Fazeli and Tess Cameron kick off the show digging into some macro trends and the potential of an incoming M&A wave. The conversation then turns to a range of topics related to China, including the impact of the stimulus, recent innovation, and the latest obesity assets & China-sourced drugs. The hosts also discuss the updates coming out of Roche’s business day, including the company’s acquisition of a CDK inhibitor from China’s Regor. On the data front, the hosts discuss Poseida and Roche’s myeloma data and J&J / Legend’s Carvytki data, then turn to other news of the week including J&J’s battle to implement a 340B rebate model, BioNTech & Instadeep AI Day updates, IGM Biosciences pivots to immunology, Harrow relaunches Triesence, and more. *This episode aired on October 4, 2024.
More description
On this week’s Biotech Hangout, hosts Josh Schimmer, Brad Loncar, Sam Fazeli and Tess Cameron kick off the show digging into some macro trends and the potential of an incoming M&A wave. The conversation then turns to a range of topics related to China, including the impact of the stimulus, recent innovation, and the latest obesity assets & China-sourced drugs. The hosts also discuss the updates coming out of Roche’s business day, including the company’s acquisition of a CDK inhibitor from China’s Regor. On the data front, the hosts discuss Poseida and Roche’s myeloma data and J&J / Legend’s Carvytki data, then turn to other news of the week including J&J’s battle to implement a 340B rebate model, BioNTech & Instadeep AI Day updates, IGM Biosciences pivots to immunology, Harrow relaunches Triesence, and more. *This episode aired on October 4, 2024.
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.